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Abstract: Uveal melanoma is the most common intraocular tumor in adults. Metastatic disease
occurs in about 30% of patients, for which there is currently no effective treatment. More than half
of patients are long-term survivors, and it is well established that cancer survivors are prone to
developing second primary cancers. In this study, we analyzed 10 years’ worth of data from the
nationwide database to determine the rates of coexisting malignancies and second primary cancers
associated with uveal melanoma. The mean annual incidence of uveal melanoma was 1.1 per million.
Approximately 43% of patients had coexisting cancers. The most common coexisting cancer was lung
cancer (10%) followed by liver cancer (6%) and non-Hodgkin lymphoma (6%). In patients whose first
cancer in their lifetime was uveal melanoma, the 10-year cumulative incidence of second primary
cancers was 22% (95% confidence interval, 9–31%). The age- and sex-adjusted standard incidence
rates was 3.61 (95% confidence interval, 2.61–4.86). The most common second primary cancers were
lung cancer and hepatocellular carcinoma, followed by prostate, thyroid, pancreatic, and ovarian
cancers. Age was the only factor associated with second primary cancer development. Our findings
will be helpful in providing counseling for cancer screening in uveal melanoma patients.
Keywords: uveal melanoma; coexisting cancer; second primary cancer; standard incidence rate
1. Introduction
Uveal melanoma is the most common intraocular tumor in adults [1,2]. Although
several of the signaling pathways involved in uveal melanoma have been discovered, this
has not translated into an increase in survival rate [3–7]. While primary uveal melanomas
respond well to radiotherapy, liver metastasis occurs in about 30% of patients, and most
patients with metastatic disease die within 2 years [8]. About 70% of uveal melanoma
patients are the long-term survivors [9].
Many cancer survivors have coexisting cancers and second primary cancers (SPCs),
a phenomenon ascribed to both environmental factors, such as smoking and occupation,
and genetic factors [10–14]. For example, patients with familial adenomatous polyposis
frequently develop colon cancer, osteoma, adrenal carcinoma, and thyroid cancer due
to the increased β-catenin activity caused by the APC gene mutation [15–17]. Women
positive for the BRCA1/2 gene mutation frequently develop hereditary breast and ovarian
cancers [18,19]. In this context, identifying cancers that accompany uveal melanoma could
help to elucidate the underlying mechanism of uveal melanoma and enable counseling
provisions for cancer screening.
Previous studies have reported that between 7.7% and 16.1% of patients with uveal
melanoma develop SPCs including skin, kidney, breast, and prostate cancers [20–23].
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Most of these studies were published before 2010, thus the incidence may have been
underestimated considering the subsequent development of cancer screening methods.
In South Korea, a national cancer screening program was introduced in 1999 and was
expanded upon thereafter. This program enables the more accurate analysis of the incidence
of coexisting cancers and SPCs. In this study, we analyzed 10 years’ worth of data from this
nationwide database to determine the rates of coexisting malignancies and SPCs associated
with uveal melanoma.
2. Materials and Methods
2.1. Data Sources
This was a nationwide, retrospective, cohort study based on the Korean Health In-
surance and Review Assessment (HIRA) database, which comprises nationwide health
insurance claim data covering approximately 98% of the total population of Korea and
including the general characteristics of the beneficiaries as well as all diagnoses, procedures,
treatments received in health care services, and inpatient and outpatient prescriptions [24].
In the HIRA database, all beneficiary and health care provider identifications are encrypted
according to the Health Insurance Portability and Accountability Act privacy rule to protect
personal information, and diagnoses are coded based on the International Classification of
Diseases 10th Revision (ICD-10). This study was approved by the Institutional Review Board
(IRB)/Ethics Committee of Severance Hospital, Yonsei University Health System (IRB
No. 4-2019-0618), which also waived the requirement for informed patient consent due to
the retrospective study design and use of de-identified data.
2.2. Study Population
Uveal melanoma patients are defined by ICD-10 code C69.3 or C69.4 as the principal or
first additional diagnosis with codes for expanding benefit coverage (V-code in Korea). Poli-
cies to expand benefit coverage commenced in 2005 and have reduced the medical expenses
for catastrophic illnesses, such as cancer and cardiocerebrovascular diseases [25]. During
the study period (January 2008 to December 2018), 702 patients with uveal melanoma were
identified. A 1-year washout period was applied to exclude prevalent uveal melanoma
cases (n = 123). We further excluded seven patients with a diagnosis of retinoblastoma as
the primary cancer. Therefore, 572 uveal melanoma patients were included in the analyses.
2.3. Definition of Coexisting Cancer and SPC
The objectives of this study were to identify coexisting cancers accompanying uveal
melanoma and to determine the incidence of SPC in patients with uveal melanoma. Coex-
isting cancer was defined as any malignancy diagnosed prior to or after the diagnosis of
uveal melanoma. SPCs were evaluated among patients diagnosed with uveal melanoma
as the first cancer in their lifetime. We defined SPC as any cancer that developed at least
6 months after the date of uveal melanoma diagnosis. In these two analyses, skin melanoma
(C43), ocular tumors (C69), and secondary cancers in which the involved site was not spec-
ified (C77–80) were not considered events of interest. Hematological cancers included
Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82–86 and C97), multiple myeloma
(C90), and leukemia (C91–95). Head and neck cancers included palate (C5), mouth (C6),
parotid gland (C7), unspecified major salivary gland (C8), tonsil (C9), oropharynx (C10),
nasopharynx (C11), unspecified lip, oral cavity, and pharynx (C14), and nasal cavity and
middle ear (C30) cancers.
2.4. Statistical Analysis
Continuous variables were presented as mean ± standard deviation, and categorical
variables are presented as frequencies and their percentages. Age at uveal melanoma diag-
nosis and the trend of the incidence rate of uveal melanoma during the study period were
examined using a linear regression model. In the SPC analysis, only patients diagnosed
with uveal melanoma as the primary cancer were included. These uveal melanoma patients
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were followed up from the date of uveal melanoma diagnosis to the date of SPC diagnosis
(event of interest), death, or the end of the study (31 December 2018), whichever came first.
The Kaplan–Meier method was used to estimate the cumulative incidence of SPC in uveal
melanoma patients. To investigate a potentially increased risk of SPC in uveal melanoma
patients compared to the general population, we calculated the standardized incidence
ratio (SIR) as the ratio of the numbers of observed to expected cases. The expected number
of cancer cases was calculated as the 5-year age-specific standard incidence rates (SIR) for
the general population multiplied by the person-years of uveal melanoma patients, using
the cancer incidence rates from 2014 reported by the Korea Central Cancer Registry [26].
The 95% confidence intervals (CIs) of the SIR were calculated using the Poisson distribution.
We then assessed the associations of age at uveal melanoma diagnosis, sex, and enucleation
with the development of SPC using a Cox proportional hazard regression model. Enucle-
ation was considered a time-varying risk factor. We further implemented the Fine and Gray
model to consider death as a competing risk [27]. For each risk factor, we implemented
a univariate model first and further investigated the association after adjusting for other
risk factors. The results are presented as hazard ratios (HRs) with 95% CIs. In all of the
analyses, a two-sided p-value < 0.05 was taken to indicate statistical significance. SAS
Enterprise Guide version 9.4 (SAS Institute Inc., Cary, NC, USA) and R 3.6.1 (R Foundation
for Statistical Computing, Vienna, Austria) were used for all statistical analyses.
3. Results
3.1. Incidence of Uveal Melanoma
Between January 2008 and December 2018, 702 patients were diagnosed with uveal
melanoma and were registered as cancer patients. After the application of a 1-year washout
period, 572 patients were included in the analysis. The median age (interquartile range of
the 297 (52%) male and 275 (48%) female patients) was 57 (47–67) years of age (Figure 1A).
The mean annual incidence rate of disease was 1.1 (range 0.9–1.5) per 1,000,000 people and
exhibited an increasing trend over time, but this was not statistically significant (Figure 1B).
Among the 572 patients, 501 (88%) and 71 (12%) had choroidal (C69.3) and ciliary body
(C69.4) tumors, respectively. During the study period, 352 patients were diagnosed with
uveal melanoma as their first cancer.
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3.2. Coexisting Cancers in Patients with Uveal Melanoma
After excluding melanoma and ocular tumors, 245 (43%) patients were found to have
coexisting cancers. Among them, 155 had one coexisting cancer, and 90 had two or more
coexisting cancers. The 381 coexisting tumors could be grouped into 51 types of cancers,
the most common of which was lung cancer in 58 (10.1%) patients, followed by liver, breast,
brain, prostate, and thyroid cancers (Table 1). The coexisting hematological cancers were
non-Hodgkin lymphoma in 32 (6%) patients and Hodgkin lymphoma in 4 (1%) patients.
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There were no patients with leukemia or multiple myeloma. Head and neck cancers were
diagnosed in 20 patients.
Table 1. Coexisting cancers associated with uveal melanoma.
ICD-10
Code Tissue n (%)
ICD-10
Code Tissue n (%)
C34 Malignant neoplasmof bronchus and lung
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Table 1. Cont.
ICD-10
Code Tissue n (%)
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Code Tissue n (%)













































































3.3. SPC in Patients with Uveal Melanoma
Among the 352 patients for whom uveal melanoma was the first cancer diagnosis,
43 (12%) developed SPCs, of which there were 15 different types (Table 2). The 10-year
cumulative incidence of SPCs was 22% (95% CI, 9–31) (Figure 2). The age- and sex-adjusted
SIR was 3.61 (95% CI, 2.61–4.86, p < 0.001), indicating a significantly higher overall cancer
risk in patients with uveal melanoma than in the general population. Data on the observed
and expected cases are presented in Table 3. The most common SPCs were lung cancer
(9 patients) and hepatocellular carcinoma (9 patients) followed by prostate (5 patients),
thyroid (4 patients), pancreatic (3 patients), and ovarian (3 patients) cancer. Most cases
of liver, pancreatic, lung, and thyroid cancer developed within the first 2 years after the
diagnosis of uveal melanoma. Prostate and ovarian cancers developed after an average of
3.2 (range, 0.8–8.7) and 5.0 (range, 1.4–6.9) years, respectively.
Table 2. Second primary cancers associated with uveal melanoma.
ICD-10
Code Tissue n (%)
C34 Malignant neoplasm of bronchus and lung 9(2.6%)
C22 Malignant neoplasm of liver and intrahepatic bile ducts 9(2.6%)
C61 Malignant neoplasm of prostate 5(1.4%)
C73 Malignant neoplasm of thyroid gland 4(1.1%)
C25 Malignant neoplasm of pancreas 3(0.9%)
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Table 2. Cont.
ICD-10
Code Tissue n (%)
C56 Malignant neoplasm of ovary 3(0.9%)
C71 Malignant neoplasm of brain 2(0.6%)
C11 Malignant neoplasm of nasopharynx 1(0.3%)
C16 Malignant neoplasm of stomach 1(0.3%)
C18 Malignant neoplasm of colon 1(0.3%)
C41 Malignant neoplasm of bone and articular cartilage ofother and unspecified sites
1
(0.3%)
C49 Malignant neoplasm of other connective and soft tissue 1(0.3%)
C50 Malignant neoplasm of breast 1(0.3%)
C76 Malignant neoplasm of other and ill-defined sites 1(0.3%)
C85 Other and unspecified types of non-Hodgkin lymphoma 1(0.3%)
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Figure 2. Cumulative incidence of second primary cancers in uveal melanoma patients.
3.4. Risk Factors for SPC Development
The associations of age, sex, and enucleation with the development of SPCs were
examined. In 352 patients with uveal melanoma as their first cancer, the mean age was
56 ± 14 years, and 182 (52%) were male. Among these patients, 115 (33%) required
enucleation during the follow-up period. SPCs developed in 43 (12%) patients, and 44
(13%) patients died. In the Cox models with and without the competing risk model, age
was the only factor associated with SPC development (Table 4). Although the hazard ratios
were higher for males and those with enucleation, the differences were not statistically
significant.
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Table 3. Estimation of second primary cancer risk in uveal melanoma patients.
Age Group
(Year)
2014 Nationwide Statistics from The Korea Central
Cancer Registry

















0–4 2,297,243.5 460 20 0 0 0
5–9 2,308,229 278 12 0 0 0
10–14 2,731,443 353 12.9 0 0 0
15–19 3,364,378.5 673 20 8.353 0 0.002
20–24 3,433,785.5 1224 35.6 17.268 0 0.006
25–29 3,151,400.5 2409 76.4 25.131 0 0.019
30–34 3,971,975.5 5363 135 61.949 0 0.084
35–39 3,875,142.5 7993 206.3 59.003 0 0.122
40–44 4,509,393.5 13,396 297.1 78.648 5 0.234
45–49 4,301,489.5 16,937 393.7 140.290 5 0.552
50–54 4,322,181.5 23,309 539.3 174.817 1 0.943
55–59 3,678,401.5 25,826 702.1 191.617 7 1.345
60–64 2,521,163 23,716 940.7 151.351 5 1.424
65–69 2,008,782 24,625 1225.90 151.020 4 1.851
70–74 1,785,086.5 27,961 1566.40 144.197 4 2.259
75–79 1,296,333.5 23,273 1795.30 109.865 7 1.972
80–84 729,676 14,052 1925.80 33.139 4 0.638
>85 477,053 8283 1736.30 26.982 1 0.468
Total 50,763,158.0 220131 433.6 1373.629 43 11.919
SIR for second primary cancers in uveal melanoma: 3.61
(95% CI, 2.61–4.86)
SPC, second primary cancer; SIR, standardized incidence ratio.
Table 4. Factors associated with the development of second primary cancers.
Cox Model Cox Model with Competing Risk
Univariate Multivariate Univariate Multivariate
Risk Factors HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value





















End of study: 267 (75%); Development of secondary primary cancers (SPCs): 43 (12%); Death: 44 (12%); HR, Hazard ratio.
4. Discussion
In a nationwide, population-based study, we showed that >40% patients with uveal
melanoma had one or more coexisting cancers. This is a higher rate than those in previous
studies reporting that ~20% patients with uveal melanoma had coexisting cancers [20,21].
The majority of those studies included patients from the 1960s to 1990s; however, the annual
cancer incidence rate and the development of cancer screening methods have increased
rapidly over the past 2–3 decades, which may explain the high rate of coexisting cancers
identified in the present study. A recent study using the Surveillance, Epidemiology, and
End Results database estimated that the long-term cumulative incidence of other primary
cancers is >40%, which is similar to the results of our study [22].
The most frequently identified coexisting cancers or SPCs reported by previous studies
conducted in white populations of uveal melanoma patients were skin melanoma, non-
melanoma skin cancer, and breast, kidney, and prostate cancers [20–23]. Our analysis
showed that uveal melanoma is frequently accompanied by lung, liver, brain, breast,
prostate, thyroid, and gastric cancers, all of which are common cancers in Korea. Breast
and prostate cancers have also been reported frequently in previous studies in white
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populations, but the rates of these other cancers differ between previous reports and the
present study. These differences in the type of coexisting cancers are thought to be due to
racial or environmental factors. Disparities in cancer incidence by race/ethnicity are well
established [28]. Melanoma and non-melanoma skin cancers are commonly diagnosed in
Caucasian but are rare in Asians [29]. Lung cancer among never smokers is increasing
in East Asians, and East Asians harboring EGFR gene mutation are far more likely to be
diagnosed with lung cancer [28,30]. Long-term exposure to particulate matter may also
contribute to the development of lung cancer in Korea. Ambient fine particles are also
associated with increased risk of breast, liver, and pancreatic cancers, which are frequently
observed co-existing cancers in our study [31]. In terms of gastric cancers, these cancers
more frequently and at an earlier age in Asians than in Caucasians, which can ascribed to
dietary habits and Helicobacter pyroli infection [28,32,33].
Intriguingly, uveal melanoma was found to be frequently accompanied by lymphoma.
Few studies have confirmed an association between lymphoma and uveal melanoma,
but an association between non-Hodgkin lymphoma and skin melanoma was suggested,
with the underlying mechanisms involving exposure to ultraviolet irradiation, commonly
shared genetic aberrations, and immune perturbations associated with chemotherapy or co-
morbidities [34–40]. A recent large-scale study of >40,000 non-Hodgkin lymphoma patients
confirmed that chemotherapy involving fludarabine and T cell activating autoimmune dis-
eases increase the risk of melanoma in non-Hodgkin lymphoma [40]. Our findings suggest
that uveal melanoma may also be associated with non-Hodgkin lymphoma. Recent studies
have shown that GNAQ mutations appear repeatedly in certain types of non-Hodgkin
lymphoma, and other studies have suggested that MYC alterations are associated with
aggressive non-Hodgkin lymphoma or a poor prognosis of uveal melanoma [41–43]. In ad-
dition, both skin melanoma and uveal melanoma arise from the melanocytes derived from
the neural crest, and therefore, immune perturbations may also promote tumorigenesis
in uveal melanoma [44]. Further studies are needed to determine whether the incidence
of uveal melanoma is actually increased in NHL survivors and to identify the associated
risk factors.
This study also analyzed the occurrence of SPCs in addition to coexisting cancers.
During the study period, 12% of patients developed SPCs, and the estimated 10-year cumu-
lative incidence was 22%, which was similar to previous studies [22,23]. The calculated SIR
in this study was higher than those in previous studies, which was likely due to a number
of differences. First, the mean age at onset of uveal melanoma in the Asian populations
is the mid-50s, which is significantly younger than the age at onset in white populations.
In a previous population-based study, patients diagnosed with uveal melanoma as their
first cancer before the age of 50 years had an elevated SPC risk [22]. Second, in Korea,
because cancer patients receive a reduction in medical expenses, patients diagnosed with
their first cancer undergo more systematic examination, and second cancers may be iden-
tified more frequently as a result. Among the risk factors that were evaluated, age was
associated with the development of SPCs, with an HR similar to those of previous studies.
Male sex and enucleation also increased the HR for SPC, but these associations were not
statistically significant.
The main limitations of our study were its retrospective nature and the limitations
inherently associated with using a publicly available database. We were unable to include
genetic and lifestyle risk factors (e.g., smoking) in the analyses. In addition, as the analysis
was conducted based on ICD-10 codes, so the detailed molecular characteristics of the can-
cers were unknown. Despite these limitations, our data can be regarded as reliable because
we defined cancers using both ICD-10 codes and the codes for expanding benefit coverage.
In conclusion, coexisting cancers were observed in more than 40% of patients with
uveal melanoma, and associations with lung cancer, liver cancer, and non-Hodgkin lym-
phoma were confirmed. The incidence of SPCs was 3.61 times higher in uveal melanoma
patients than in the reference population. Our findings will be useful in providing counsel-
ing for cancer screening in uveal melanoma patients.
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